METTL3 and neoplasm: METTL3 deficiency in TAMs downregulates m6A modification on IRAKM, which, in turn, slows down its degradation and suppresses TLR signaling-mediated TAM activation, inhibiting proinflammatory cytokine expression and promoting tumor progression (Figure 3) (104).